SEC Filing Summary: Prima Biomed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima Biomed Ltd, a foreign private issuer headquartered in Sydney, Australia, on July 18, 2017. The registrant files annual reports under Form 20-F. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a cover sheet and exhibit index rather than a financial statement.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document includes an exhibit index listing Exhibit 99.1 as "Appendix 4C," but the content of this appendix is not included in the provided text.
Key Facts for Investor Verification
- The filing date is July 18, 2017.
- The registrant is Prima Biomed Ltd, not Immutep Ltd as indicated in the request metadata.
- The document contains no financial data; investors must review the referenced Exhibit 99.1 (Appendix 4C) for substantive information.
- The Chief Executive Officer, Marc Voigt, signed the report.